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EDITORIAL COMMENT
Endovascular Aneurysm Repair
With the AneuRx Stent-Graft Is
Safe, But Is it Effective?*
Timothy A. M. Chuter, MD, FACS
San Francisco, California
In this issue of the Journal, Howell et al. (1) present some
tuly remarkable results. Working in an interventional car-
diology suite, they were able to implant the Medtronic
AneuRx stent graft in all but one of 215 patients. Most of
these patients had major comorbidity with an American
Society of Anesthesiologists grade of IV or higher in 58.6%
of patients. All these sick patients underwent stent-graft
implantation under general anesthesia, yet only one patient
suffered a non–Q-wave myocardial infarction, none died in
the perioperative period, and most went home the next day.
See page 1040
One notable aspect of the technique described by Howell
et al. (1) is the use of the Prostar XL device to facilitate
percutaneous arterial closure. The 16F contralateral access
site was closed this way in 174 of 188 attempts, and the 22F
ipsilateral access site was closed in 26 of 27 attempts. Few
centers have achieved such a high rate of success with
percutaneous arterial insertion of large-bore sheaths. In-
deed, one wonders, given their results, why Howell et al. (1)
did not attempt totally percutaneous repair in more cases.
Based on these results, one can certainly say endovascular
aneurysm repair with the AneuRx device was safe, but one
cannot say it was effective. The efficacy of endovascular
aneurysm repair is usually assessed by the number of
endoleaks (types 1 and 3), the rate of diameter change, and
the incidence of rupture.
In the report by Howell et al. (1), the data on early
endoleak are marred by a reliance on intraoperative angiog-
raphy. Most of the patients in their study (1) had contrast-
enhanced computed tomography (CT) prior to discharge
from the hospital and again one month later, yet these data
are not presented. Nevertheless, the rate of endoleak is close
to the rate seen in multicenter studies of the AneuRx device.
For example, the core laboratory data for the Food and
Drug Administration (FDA) study (2) show an early en-
doleak rate of 50%. Most of these leaks are designated type
IV based on their diffuse appearance. This type of endoleak,
through tiny holes in the fabric, is often assumed to be
self-limited and of no significance, an assumption that may
be ill founded. Holes in the fabric can transmit pressure to
the aneurysm, even when they are small and plugged with
thrombus. In my opinion, the porosity of the AneuRx graft
accounts for the lower rate of aneurysm shrinkage relative to
the rate seen with less porous stent grafts, such as the
Guidant Ancure device (3).
The high rate of late rupture following endovascular
aneurysm repair with the AneuRx device is a particular
cause for concern (4,5). If one excludes the cases of
perioperative rupture, the mean time to rupture of published
cases was almost two years (4). Howell et al. (1) are not in
the position to assess this aspect of device performance,
because only 22 of their 214 patients were followed longer
than two years. According to a recent health care advisory,
the FDA has information on 25 cases of late rupture. This
is a small number relative to the total number of devices
inserted, but more worrisome when considered as a propor-
tion of the small number of long-term implants.
The AneuRx device is not the only one associated with a
high incidence of late rupture. Worldwide, even more cases
of rupture followed repair with the Vanguard device. It is
instructive to remember that the Vanguard, and its precur-
sor the Stentor, looked very promising in the short-to-
medium term (6), and by the time that problems became
apparent, many patients had been treated. Other devices are
less prone to late aneurysm rupture. For example, not a
single case of late rupture has been reported following
treatment with an Ancure bifurcated stent graft.
Reports of fabric tears, stent fractures, component sepa-
ration, and migration are also worrisome. A recent study
from Italy (7) showed migration of 10 mm or more in
approximately 27% of AneuRx cases at three years. The
corresponding incidence for the Ancure device was 0.5%
(8).
In conclusion, every aspect of stent-graft function is
device specific. Some devices are stable and effective, but
others are not. The excellent results reported by Howell et
al. (1) show that the AneuRx device can be safely implanted
in an interventional suite. In two more years they will have
the data to show whether or not this operation provided
durable protection from aneurysm rupture.
Reprint requests and correspondence: Dr. Timothy A. M.
Chuter, Division of Vascular Surgery, UCSF, 505 Parnassus
Ave., M-488, San Francisco, California 94143. E-mail: chutert@
surgery.ucsf.edu.
REFERENCES
1. Howell MH, Strickman N, Mortazavi A, Hallman CH, Krajcer Z.
Preliminary results of endovascular abdominal aortic aneurysm exclu-
sion with the AneuRx stent-graft. J Am Coll Cardiol 2001;38:1040–6.
2. Zarins CK, White RA, Hodgson KJ, et al. Endoleak as a predictor of
outcome after endovascular aneurysm repair: AneuRx multicenter clin-
ical trial. J Vasc Surg 2000;32:90–107.
3. Makaroun MS. The Ancure endografting system: an update. J Vasc
Surg 2001;33:S129–34.
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Division of Vascular Surgery, University of California at San Francisco,
San Francisco, California.
Journal of the American College of Cardiology Vol. 38, No. 4, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01517-0
4. Zarins CK, White RA, Moll FL, et al. The AneuRx stent graft:
four-year results and worldwide experience 2000. J Vasc Surg 2001;33:
S135–45.
5. FDA Public Health Notification: Problems with endovascular grafts for
treatment of abdominal aortic aneurysm (AAA). April 27, 2000.
6. Beebe HG, Cronenwett JL, Katzen BT, et al. Results of an aortic
endograft trial: impact of device failure beyond 12 months. J Vasc Surg
2001;33:S55–63.
7. Cao P, Verzini F, De Rango P, et al. Device migration after endolu-
minal AAA repair: analysis of 83 cases with minimum follow-up of 2
years. Presented at the Society for Vascular Surgery, Baltimore, MD,
June 10, 2001.
8. Makaroun MS, Chaikof EL, Naslund T, Matsumura J. Efficacy of the
bifurcated Ancure endograft versus open repair of abdominal aortic
aneurysm: a reappraisal. Presented at the Society for Vascular Surgery,
Baltimore, MD, June 10, 2001.
1048 Chuter JACC Vol. 38, No. 4, 2001
Editorial Comment October 2001:1047–8
